Table 3 Worst nonhaematologic CTC toxicity grade per patient for all cycles

From: A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb–IV non-small-cell lung cancer who failed first-line treatment

 

Docetaxel

Docetaxel–Irinotecan

 

Toxicity

No.

%

No.

%

P

ASAT

    

NS

 1

6

11

4

8

 

 2

1

2

0

0

 

 3

0

0

1

2

 

ALAT

    

NS

 1

20

36

18

35

 

 2

4

7

3

6

 

Creatinine

    

NS

 1

21

38

8

15

 

 2

1

2

3

6

 

 3

0

0

1

2

 

Mucositis

    

NS

 1

8

14

5

10

 

 2

1

2

0

0

 

Nausea

    

NS

 1

15

27

14

27

 

 2

5

9

12

23

 

Vomiting

    

NS

 1

11

20

9

17

 

 2

4

7

4

8

 

Diarrhoea

    

<0.01

 1

11

20

21

40

 

 2

4

7

11

21

 

 3

1

2

7

14

 

Fever

    

NS

 1

5

9

2

4

 

 2

2

4

0

0

 

Infections

    

NS

 1

3

5

2

4

 

 2

0

0

2

4

 

 3

1

2

0

0

 

Alopecia

    

<0.05

 1

15

27

6

12

 

 2

16

29

25

48

 

Skin reactions

    

NS

 1

2

4

0

0

 

 2

3

5

0

0

 

Sensory neuropathy

    

NS

 1

13

23

10

19

 

 2

4

7

1

2

 

Motoric neuropathy

    

NS

 1

2

4

0

0

 

 2

0

0

0

0

 

 3

0

0

1

2

 

Anorexia

    

NS

 1

16

29

16

31

 

 2

4

7

4

8

 

Fatigue

    

NS

 1

23

41

13

25

 

 2

12

21

18

35

 

Nail changes

    

0.052

 1

5

9

0

0

 

 2

1

2

0

0

 

Myalgia

    

<0.05

 1

12

21

3

6

 

 2

2

4

0

0

 

Arthralgia

    

<0.05

 1

5

9

0

0

 
  1. NS=Not significant.
Back to article page